5 Best Low-Risk Investments in May 2026

3. Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating and a $36 price target for Pfizer Inc. (NYSE:PFE) as the firm revised its financial forecast ahead of the company’s Q1 earnings announcement on May 5.

The firm anticipates first-quarter revenues of around $13.8 billion, compared to average predictions of $13.9 billion, and earnings per share of $0.76 vs $0.72. Full-year 2026 revenue and EPS expectations come in at $61.3 billion and $3, respectively, contrary to the consensus of $61.2 billion and $2.96.

The key adjustment in Guggenheim’s forecast is a substantial upward adjustment to Eliquis, which the firm thinks has better IRA net price dynamics than the market projected.

Guggenheim anticipates investor attention to focus on impending pipeline readouts, which the firm thinks will help drive expansion for the company as it deals with the 2026-2028 era of major patent expirations.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. The company offers medicines and vaccines in various therapeutic areas.